The Brain Booster
Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog)
Semax is a synthetic peptide analog of ACTH (adrenocorticotropic hormone) fragment 4-10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia as a pharmaceutical for stroke recovery, cognitive enhancement, and neuroprotection. Semax is one of the most well-studied nootropic peptides, with over 800 published studies.
Semax primarily works by dramatically increasing BDNF expression in the brain, promoting neurogenesis, synaptic plasticity, and neuroprotection. It also modulates multiple neurotransmitter systems to enhance cognitive performance.
Upregulates BDNF (brain-derived neurotrophic factor) expression by 200-800% in key brain regions, promoting neuroplasticity and memory formation.
Enhances dopaminergic and serotonergic neurotransmission, improving motivation, focus, and mood stability.
Provides neuroprotective effects by reducing oxidative stress and inhibiting neuroinflammatory cascades in brain tissue.
Modulates NGF (nerve growth factor) expression, supporting neuronal survival and the growth of new neural connections.
Significant improvements in memory consolidation, recall speed, and learning capacity through BDNF-mediated neuroplasticity enhancement.
Enhances sustained attention and information processing through dopaminergic modulation without stimulant-like side effects.
Protects neurons from oxidative damage and excitotoxicity, with clinical applications in stroke recovery and neurodegenerative conditions.
Approved in Russia for acute ischemic stroke treatment, with clinical data showing improved neurological outcomes when administered early.
Semax increased BDNF mRNA expression by 200-800% in rat hippocampus and cortex, with effects lasting several hours after administration.
Clinical studies in stroke patients showed Semax administration within 6 hours of onset significantly improved neurological outcomes at 30-day follow-up.
Chronic Semax administration enhanced cognitive function and reduced anxiety-like behavior in animal models without producing tolerance or dependence.
Semax has been used as an approved pharmaceutical in Russia since 1994, providing decades of clinical safety data. It is non-addictive, does not produce tolerance, and has minimal side effects. The intranasal route is the standard delivery method.
Research Status
Semax has over 800 published studies and is approved as a pharmaceutical in Russia. Clinical evidence is robust for stroke recovery and cognitive enhancement. Western clinical trials are limited but preclinical data is strong.
Regulatory Note
Approved pharmaceutical in Russia since 1994. Not FDA-approved in the US. Available as a research compound through compounding pharmacies.